XORTX End Period Cash Flow from 2010 to 2024

XRTX Stock  USD 1.21  0.02  1.68%   
XORTX Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2024. During the period from 2010 to 2024, XORTX Therapeutics End Period Cash Flow regression line of annual values had r-squared of  0.32 and arithmetic mean of  2,186,657. View All Fundamentals
 
End Period Cash Flow  
First Reported
2014-03-31
Previous Quarter
3.1 M
Current Value
2.3 M
Quarterly Volatility
5.2 M
 
Yuan Drop
 
Covid
Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 996.5 K, Other Operating Expenses of 2.6 M or Total Operating Expenses of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.89. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of XORTX Therapeutics Correlation against competitors.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Latest XORTX Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of XORTX Therapeutics over the last few years. It is XORTX Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XORTX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

XORTX End Period Cash Flow Regression Statistics

Arithmetic Mean2,186,657
Geometric Mean48,939
Coefficient Of Variation204.50
Mean Deviation3,128,538
Median58,614
Standard Deviation4,471,624
Sample Variance20T
Range14.8M
R-Value0.56
Mean Square Error14.7T
R-Squared0.32
Significance0.03
Slope563,135
Total Sum of Squares279.9T

XORTX End Period Cash Flow History

20243.6 M
20233.4 M
202210.4 M
202114.8 M
2020171.3 K
201958.6 K
2018260 K

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow3.4 M3.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.